8-K: FONAR Reports Q3 Fiscal 2026 Financial Results

FONAR Corporation announced its financial results for the third quarter and nine-month period of Fiscal Year 2026, reporting decreases in net income and income from operations.

Summary

• FONAR Corporation reported financial results for the third quarter and nine months ended March 31, 2026.
• Total Revenues-Net for the third quarter decreased by 3% to $26.5 million compared to the same quarter in Fiscal 2025.
• For the nine-month period, Total Revenues-Net increased slightly by 1.3% to $78.1 million.
• Income from Operations for the third quarter decreased by 33% to $2.4 million.
• Net Income for the third quarter decreased by 25% to $2.3 million, with Diluted Net Income Per Common Share falling 35% to $0.24.
• For the nine-month period, Net Income decreased by 19% to $7.5 million, and Diluted Net Income Per Common Share decreased by 21% to $0.89.
• Total Cash, Cash Equivalents and Short-Term Investments were $53.8 million as of March 31, 2026, a decrease of 4% from June 30, 2025.
• The company is proceeding with a proposed 'going private' transaction led by its CEO and COO, with a special committee evaluating the proposal.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant declines in key profitability metrics like net income and income from operations, despite growth in scan volume and revenues for the nine-month period.

Positives

• Total Revenues-Net for the nine-month period increased to $78.1 million from $77.1 million in the prior year.
• Total scan volume in the third quarter of Fiscal 2026 was a record 55,660, a 1.5% increase over the previous quarter and a 1.8% increase over the corresponding quarter of Fiscal 2025.
• MRI scan volume for the first nine months of fiscal 2026 was 165,612, a 3.0% increase over the corresponding period in Fiscal 2025.
• The company's diagnostic imaging management subsidiary, Health Management Company of America (HMCA), continues to grow, managing 45 MRI scanners compared to 9 in 2009.
• Total Assets increased to $219.2 million from $216.9 million.
• Total Stockholders Equity increased to $178.6 million from $172.6 million.
• The Current Ratio improved to 9.2 from 8.4.
• Working Capital increased by 4% to $131.9 million.

Negatives

• Net Income for the third quarter decreased 25% to $2.3 million compared to the prior year's quarter.
• Income from Operations for the third quarter decreased 33% to $2.4 million.
• Diluted Net Income Per Common Share for the third quarter decreased 35% to $0.24.
• Total Revenues-Net for the third quarter decreased 3% to $26.5 million.
• Selling, general & administrative costs (SG&A) increased 5% to $8.4 million for the quarter.
• Net Cash Provided by Operating Activities for the nine-month period decreased to $3.4 million from $7.0 million.
• Total Cash, Cash Equivalents and Short-Term Investments decreased by 4% to $53.8 million.

Risks

• The consummation of the proposed 'going private' transaction remains subject to various conditions, including stockholder approval and other customary closing conditions, with no assurance of completion or timing.
• Potential difficulties in employee retention as a result of the proposed transaction.
• Risks related to disruption of management's attention from the Company's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the Company's relationships with referral sources and vendors, operating results, and business generally.
• Changes in global, regional, or local political, economic, business, competitive, market, regulatory, and other factors.
• The Company cautions against undue reliance on forward-looking statements due to potential material differences between actual results and those expressed or implied.

Future Outlook

The company expects to be managing an entirely new MRI center in Nassau County before the end of Fiscal 2026 and continues to search for new locations. The consummation of the proposed 'going private' transaction is subject to stockholder approval and other closing conditions.

Management Comments

• "I am pleased to report that our diagnostic imaging management subsidiary, Health Management Company of America (HMCA), the Company's primary source of revenue and profit, continues to grow."
• "We currently manage 45 MRI throughout New York and Florida."
• "Total scan volume in the third quarter of Fiscal 2026 was a record 55,660, 1.5% over that of the previous quarter... and 1.8% higher than that of the corresponding quarter of Fiscal 2025."
• "Referring doctors appreciate that if they refer their patients to an HMCA-managed, multi-scanner center, their patients will not have to wait days and days for their MRIs."
• "We expect to be managing an entirely new MRI center in Nassau County before the end of Fiscal 2026."
• "As always, we continue to search for locations where the introduction of our technology and services would profitably enhance our existing New York and Florida networks."
• "There can be no assurance that the merger will be consummated or as to the timing of any such consummation."
• "As always, I remain grateful to our management team and all of our employees for making our company a success."

Industry Context

StockSavvy.ai notes that FONAR's results reflect a mixed performance within the diagnostic imaging sector, with growth in scan volume driven by its subsidiary HMCA, but a decline in profitability metrics. The company's focus on specialized MRI technology, like the UPRIGHT Multi-Position MRI, positions it uniquely, but the overall financial results indicate pressure on margins or increased operating costs.

Legal Proceedings

• The filing mentions the potential outcome of legal proceedings that may be instituted against the Company and others following the announcement of the Merger Agreement as a risk factor.

Related Party Transactions

• Medical receivable from related parties.
• Management and other fees receivable from related medical practices.
• Service and repair fees related parties.
• Management and other fees related medical practices.
• Interest income from related party.
• Note receivable from related party.
• Due to related party medical practices.
• Unearned revenue on service contracts from related parties.

Stakeholder Impact

• Shareholders: The proposed 'going private' transaction may impact shareholders, with a special committee evaluating the proposal. The decline in financial performance could affect shareholder value if the transaction does not proceed or is at an unfavorable valuation.
• Employees: Potential difficulties in employee retention are noted as a risk associated with the proposed transaction.
• Customers/Referring Physicians: Continued growth in scan volume and record scan numbers suggest ongoing demand for services. The ability to avoid scheduling backlogs is appreciated by referring doctors.
• Creditors: No specific impact on creditors is mentioned, but the company's financial health is a general consideration.

Next Steps

• Obtain stockholder approval for the proposed 'going private' transaction at the special meeting scheduled for May 28, 2026.
• Satisfy other customary closing conditions for the merger.
• Manage a new MRI center in Nassau County before the end of Fiscal 2026.
• Continue to search for new locations for technology and service introduction.

Key Dates

Recommendation

The company shows growth in scan volume and revenue for the nine-month period, driven by its subsidiary HMCA, and is progressing with a 'going private' transaction. However, significant declines in profitability metrics for the quarter and nine-month periods, coupled with the uncertainty surrounding the merger's completion, warrant a cautious 'hold' stance.

Keywords

FONAR, MRI, Financial Results, Q3 2026, HMCA, Diagnostic Imaging, SEC Filing, 8-K